Skip to main content
SpringerLink
Log in

Serum tumour markers in renal failure

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

In order to assess the clinical value of six tumour markers in pre-dialysis patients with chronic renal failure as well as in patients on regular haemodialysis, we studied these markers in 35 predialysis patients, 35 patients on chronic haemodialysis and 35 healthy controls. Serum squamous cell antigen (SCC), CA 19.9, and CA 125 levels were found to be elevated in the uraemic groups as compared to the normal controls. Carcinoembryonic antigen (CEA), alpha foetoprotein (AFP), and prostate-specific antigen (PSA) levels were within normal limits in all groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Matas, A. J., Simmons, R. L., Kjellstrand, C. M., Buselmeir, T. J., Najarian, J. S.: Increased incidence of malignancy during chronic renal failure.Lancet, 1, 883 (1975).

    Article  PubMed  CAS  Google Scholar 

  2. Kinlen, L. J., Eastwood, J. B., Kerr, D. N.: Cancer in patients receiving dialysis.Br. Med. J., 1, 1401 (1980).

    Google Scholar 

  3. Slifkin, R. F., Goldberg, J., Neff, M. S.: Malignancy in end stage renal disease.Trans. Am. Soc. Artif. Intern. Organs, 23, 34 (1977).

    PubMed  CAS  Google Scholar 

  4. Lindler, A., Farewell, V. T., Sherrard, D. J.: High incidence of neoplasia in uremic patients receiving long-term hemodialysis.Nephron, 27, 292 (1981).

    Google Scholar 

  5. Bush, A., Gabriel, R.: Cancer in uremic patients.Clin. Nephrol., 22, 77 (1984).

    PubMed  CAS  Google Scholar 

  6. Pecquek, J. C., Schwarz, A., Dieckmann, K. D., Offermann, G.: Cancer incidence in patients on chronic dialysis and in renal transplant recipients.Urol. Int., 45, 290 (1990).

    Article  Google Scholar 

  7. Kantar, A. F., Hoover, R. N., Kinlen, L. J., McMullan, M. R., Fraumeri, J. F.: Cancer in patients receiving long term dialysis treatment.Am. J. Epidemiol., 126, 370 (1987).

    Google Scholar 

  8. Port, F. K., Nawal, E., Raghep, M. P. H., Schwartz, A. G., Hawthorne, V. M.: Neoplasms in dialysis patients: A population-based study.Am. J. Kidney Dis., 2, 119 (1989).

    Google Scholar 

  9. Bates, S. E.: Clinical applications of serum tumor markers.Ann. Intern. Med., 115, 623 (1991).

    PubMed  CAS  Google Scholar 

  10. Odagiri, E., Jibiki, K., Takedo, M., Sugimura, H., Iwachika, C., Abe, Y., Kihara, K., Kihara, Y., Hov, M., Namura, T., Kuba, K., Sugino, N., Ohta, K., Demura, R., Demura, H.: Effect of hemodialysis on the concentration of the seven tumor markers: Carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-related antigen, neuron-specific enolase, CA 125, CA 19-9 and CA 15-3 in uremic patients.Am. J. Nephrol., 11, 363 (1991).

    PubMed  CAS  Google Scholar 

  11. Zeferos, N., Digenis, G. E., Christophoraki, M., Alexopoulos, I., Kostakis, A., Gyftaki, H., Moulopoulos, S.: Tumor markers in patients undergoing hemodialysis and kidney transplantation.Nephron, 59, 618 (1991).

    PubMed  CAS  Google Scholar 

  12. Filello, X., Cases, A., Molino, R., Jo, J., Bedini, J. L., Revert, L., Ballesto, A. M.: Tumor markers in patients with chronic renal failure.Int. J. Biol. Markers, 5(2), 85 (1990).

    Google Scholar 

  13. Cases, A., Filello, X., Molino, R., Balesta, A. M., Pedret, J. L., Revert, L.: Tumor markers in chronic renal failure and hemodialysis patients.Nephron, 57, 183 (1991).

    PubMed  CAS  Google Scholar 

  14. De Santo, N. G., Venerosa, S., Capadicaso, G.: Tumor markers in uremia; carcinoembryonic antigen, neuron-specific enolase, carbohydrate antigen CA-50 and alphafetoprotein.Am. J. Nephrol., 6, 458 (1986).

    Article  Google Scholar 

  15. Ammon, A., Eiffert, H., Weber, M. H.: Tumor markers in dialysis-dependent renal failure: A comparison of the mucin-like carcinoma antigen CA 15.3, CA-125, CA 19.9, and CEA antigens.Oncology, 11, 260 (1988).

    Article  CAS  Google Scholar 

  16. Inamoto, H., Ozoki, R., Matsuzaki, T., Wakut, M., Saruta, T., Osawa, A.: Incidence and mortality pattern of malignancy and factors affecting the risk of malignancy in dialysis patients.Nephron, 59, 611 (1991).

    PubMed  CAS  Google Scholar 

  17. Docci, D., Pistocchi, E., Turci, F., Baldrati, L., Urbini, S., Scaioli, S. Serum CA 19.9 and CA 50 antigens in hemodialysis patients.Clin. Nephrol., 27 (4), 179 (1987).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Ondokuz Mayis University, Samsun, Turkey

    N. Arik, T. Akpolat & K. Hasil

  2. Department of Biochemistry, Ondokuz Mayis University, Samsun, Turkey

    B. Adam

  3. Department of Public Health, Ondokuz Mayis University, Samsun, Turkey

    S. Tabak

Authors
  1. N. Arik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Akpolat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Hasil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Tabak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arik, N., Adam, B., Akpolat, T. et al. Serum tumour markers in renal failure. International Urology and Nephrology 28, 601–604 (1996). https://doi.org/10.1007/BF02550974

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02550974

Keywords

Search

Navigation